Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial
Psoriasis therapeutic market estimated to reach $11.4B in 2020 Distribution deals for the psoriasis indication are in place for Canada,…
Pharmaceuticals, Biotechnology and Life Sciences
Psoriasis therapeutic market estimated to reach $11.4B in 2020 Distribution deals for the psoriasis indication are in place for Canada,…
Inceptua Medicines Access, a business unit of the Inceptua Group, has announced the collaboration with Onconova Therapeutics to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.
– ARQ 531 demonstrates substantial anti-tumor activity and manageable safety profile – Eight of nine evaluable CLL patients initially dosed…
Leading investors participating in this round include Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Surveyor Capital…
Interim data show that patients with CLL achieved overall best objective response rate of 85% with progression-free survival of 100%…
Agreement Supports Lantheus’ Microbubble Franchise Growth Strategy and Expansion into Oncology NORTH BILLERICA, Mass.–(BUSINESS WIRE)–Lantheus Holdings, Inc. (the “Company”) (NASDAQ:…
CHENGDU, China–(BUSINESS WIRE)–HitGen Inc. (“HitGen”) is pleased to announce that the company has entered into a strategic collaboration with Janssen…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune…
ALPN-101 demonstrates ability to potently inhibit both T and B cell responses in first-in-human study Human experience supports both IV…
CAMBRIDGE, England & MOSCOW–(BUSINESS WIRE)–IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, has been…